MSB Trading - 2020, page-8956

Interesting MSB didn't even cop a mention.

I was looking to purchase, but I didn't realise their was so much competition in the space.

Can't say this is a CSL as it's different biotech technology where as CSL is hugely diversified in vaccines which is much more scalable and obviously cheaper to administer.

Half the problem with stock forums is they are usually very biased to the positive and can become cult like as people fall in love with a stock or story because they feel it’s the path to easy riches.

I personally like to read the counter arguments as well to stay balanced.

I hope everyone makes an absolute motsa, but keep your feet on the ground as MSB has been a poor performer with a poor track record on delivery after $440 million of past dilution, so their are still big risks.

DYOR